Technology
Health
Biotechnology

Actinium Pharmaceuticals

$0.55
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.009 (-1.61%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ATNM and other stocks, options, ETFs, and crypto commission-free!

About

Actinium Pharmaceuticals, Inc, also called Actinium Pharmaceuticals, is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies to cell therapies. The firm's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells. Read More Its product pipeline includes Iomab-B, Actimab-A, and Actimab-M. The company was founded in 1993 and is headquartered in New York, NY.

Employees
30
Headquarters
New York, New York
Founded
1993
Market Cap
64.68M
Price-Earnings Ratio
β€”
Dividend Yield
0.00
Average Volume
1.12M
High Today
$0.5737
Low Today
$0.54
Open Price
$0.5577
Volume
706.91K
52 Week High
$0.8651
52 Week Low
$0.3323

Collections

Technology
Health
Biotechnology
2013 IPO
US
North America

News

Yahoo FinanceMar 7

What Type Of Shareholder Owns Actinium Pharmaceuticals, Inc.’s (NYSEMKT:ATNM)?

A look at the shareholders of Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) can tell us which group is most powerful. Institutions often own shares in more established companies, while it’s not unusual to see insiders own a fair bit of smaller companies. Companies that used to be publicly owned tend to have lower insider ownership. With a market capitalization of US$68m, Actinium Pharmaceuticals is a small cap stock, so it might not be well known by many institutional investors. Our analysis of the ownersh...

541
MarketBeatMar 6

Stock Price, News, & Analysis for Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The company is also developing Actimab-A, which is in Phase II clinical trials for the treatm...

46

Earnings

-$0.14
-$0.11
-$0.07
-$0.04
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.06 per share
Actual
-$0.05 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.